Formycon AG (FRA:FYB)
22.50
+0.40 (1.81%)
At close: Sep 29, 2025
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€211,339
Profits / Employee
€692,939
Market Cap
397.45M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 250 | 12 | 5.04% |
Dec 31, 2023 | 238 | 33 | 16.10% |
Dec 31, 2022 | 205 | 34 | 19.88% |
Dec 31, 2021 | 171 | 40 | 30.53% |
Dec 31, 2020 | 131 | 18 | 15.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Siemens Energy AG | 98,000 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Deutsche Bank Aktiengesellschaft | 89,753 |
Formycon AG News
- 13 days ago - Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy • news - Onvista
- 13 days ago - EQS-News: Horus Pharma becomes additional commercialization partner for Formycon's Eylea biosimilar FYB203 in selected European countries under the brand name Baiama - Wallstreet:Online
- 6 weeks ago - Formycon Boosts Working Capital, Stays on Track for Year-End Goals - Wallstreet:Online
- 6 weeks ago - EQS-News: Formycon confirms full-year guidance following business development in line with plan – working capital raised - Wallstreet:Online
- 2 months ago - EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025 - Wallstreet:Online
- 2 months ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] - Wallstreet:Online
- 2 months ago - EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda biosimilar candidate FYB206 - Wallstreet:Online
- 3 months ago - EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta (ranibizumab) across Sub-Saharan Africa - Wallstreet:Online